文献速递心律失常

室上性心动过速导管消融后长期症状改善与患者满意度:德国消融注册研究

Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German ablation registry.
PubMed 文献 · Eur Heart J · 2017-01-01

该前瞻性德国消融质量注册研究纳入2007年1月至2010年1月间接受室上性心动过速(SVT)导管消融的12566例患者并随访至少1年,围术期成功率为96.3%,1年Kaplan-Meier死亡估计为1.4%,消融或其他症状性SVT复发见于3783例(32.6%),1年后74.1%的存活者认为消融治疗成功。结论认为SVT消融是安全的,可使四分之三的患者在1年后获得症状改善与满意度;心房扑动(AFL)患者随访中死亡率和卒中率显著偏高,作者认为其显然需要一致的长期抗凝和更多医疗关注。

要点

  • 围术期成功率为96.3%,范围自84.3%(局灶性房性心动过速)至98.9%(房室结折返性心动过速)。
  • 消融或其他症状性SVT复发见于3783例(32.6%),范围自17.2%(房室结折返性心动过速)至45.6%(心房颤动)。
  • 1年后74.1%的存活者认为消融成功;即使复发者中76.0%认为成功或部分成功,89.6%仍愿在同一机构再次消融。

核心结论

  • SVT消融是安全的,1年后使四分之三的患者获得症状改善与满意度。
  • 即使存在心律失常复发,仍可记录到较高的满意度水平和对消融机构的依从性。
  • AFL患者随访中死亡率和卒中率显著偏高,作者认为其显然需要一致的长期抗凝和更多医疗关注。

研究设计与样本

  • 前瞻性德国消融质量注册研究,纳入2007年1月至2010年1月间接受SVT导管消融的12566例患者,随访至少1年。
  • 消融类型构成:心房颤动占37.2%的操作、心房扑动29.9%、房室结折返性心动过速23.2%、房室折返性心动过速6.3%、局灶性房性心动过速3.4%。

主要发现

  • 围术期成功率为96.3%,范围自84.3%(局灶性房性心动过速)至98.9%(房室结折返性心动过速)。
  • 1年Kaplan-Meier死亡估计总体为1.4%,心房扑动组高达2.6%,局灶性房性心动过速组为2.8%。
  • 消融或其他症状性SVT复发见于3783例(32.6%),范围自17.2%(房室结折返性心动过速)至45.6%(心房颤动);12.0%的患者接受了再次消融。
  • 1年后74.1%的存活者认为消融治疗成功,15.7%认为部分成功,9.6%认为不成功。
  • 即使存在心律失常复发,76.0%认为消融成功或部分成功,89.6%仍愿在同一机构再次接受消融。

临床怎么用

  • 作者认为AFL患者显然需要一致的长期抗凝和更多医疗关注。
  • SVT消融可使四分之三的患者在1年后获得症状改善与满意度,即使复发者中多数仍认可该治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To analyse outcomes of supraventricular tachycardia (SVT) ablations performed within a prospective German Ablation Quality Registry. METHODS AND RESULTS: Data from 12 566 patients who underwent catheter ablation of SVT between January 2007 and January 2010 to treat atrial fibrillation (AFIB, 37.2% of procedures), atrial flutter (AFL, 29.9%), atrioventricular nodal re-entrant tachycardia (AVNRT, 23.2%), atrioventricular re-entrant tachycardia (6.3%), and focal atrial tachycardia (AT, 3.4%) were prospectively collected. Patients were followed for at least 1 year. The periprocedural success rate was 96.3%, ranging from 84.3% (focal AT) to 98.9% (AVNRT). Kaplan-Meier mortality estimate at 1 year was 1.4% overall, and as high as 2.6% in the AFL group and 2.8% in the focal AT group. Recurrence of ablated or another symptomatic SVT was observed in 3783 (32.6%) of patients, ranging from 17.2% (AVNRT) to 45.6% (AFIB). Repeat ablation was performed in 12.0% of patients. After 1 year, 74.1% of survivors perceived ablation therapy as successful, 15.7% as partly successful, and 9.6% as unsuccessful. Even in those patients with arrhythmia recurrence, 76.0% perceived ablation as successful or partly successful and 89.6% would still undergo repeat ablation in the same institution. CONCLUSION: Ablation therapy for SVT is a safe procedure bringing symptomatic improvement and satisfaction to three quarters of patients after 1 year. Even in patients with arrhythmia recurrence, a high satisfaction level and adherence to the ablating institution could be documented. Strikingly high mortality and stroke rates in follow-up were observed in AFL patients, who apparently need consistent long-term anticoagulation and more medical attention.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Brachmann J, Lewalter T, Kuck KH, et al. Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German ablation registry. Eur Heart J. 2017. PMID: 28329395. doi:10.1093/eurheartj/ehx101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。